Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
GENOCEA BIOSCIENCES, INC. (GNCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/10/2022 8-K Quarterly results
10/28/2021 8-K Quarterly results
Docs: "Genocea Provides Third Quarter 2021 Corporate Update GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues"
07/29/2021 8-K Quarterly results
Docs: "Genocea Provides Second Quarter 2021 Corporate Update GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues"
04/29/2021 8-K Quarterly results
Docs: "Genocea Provides First Quarter 2021 Corporate Update GEN-011 and GEN-009 immuno-oncology programs continue to advance"
10/29/2020 8-K Quarterly results
Docs: "Genocea Provides Third Quarter 2020 Corporate Update Initiated GEN-011 Phase1/2a clinical trial Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy"
07/23/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "Genocea Provides First Quarter 2020 Corporate Update Clinical stage programs GEN-009 and GEN-011 continue to advance Anticipate GEN-011 IND filing in Q2 Expect GEN-009 Phase 1/2a Part B readout in Q3 GEN-011 Virtual Symposium planned for May 12 th Conference call today at 8:30 a.m. EDT"
10/24/2019 8-K Quarterly results
07/25/2019 8-K Quarterly results
Docs: "Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009; Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call today at 8:30 am ET"
04/30/2019 8-K Quarterly results
Docs: "Genocea Provides Corporate Update, Including First-Quarter 2019 Financial Results Company anticipates presenting first GEN-009 immunogenicity data at ASCO 2019 Conference call today at 9:00 am ET"
02/28/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "Genocea Reports Third Quarter 2018 Financial and Operating Results Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patients Presenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET"
08/02/2018 8-K Quarterly results
Docs: "Genocea Reports Second Quarter 2018 Financial and Operating Results Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial underway ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification Conference call today at 9:00 am ET"
05/10/2018 8-K/A Quarterly results
Docs: "Genocea Reports First Quarter 2018 Financial and Operating Results - Company files IND for lead neoantigen vaccine program, GEN-009 - - ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification - - Conference call today at 9 am ET -"
05/10/2018 8-K Quarterly results
Docs: "Genocea Reports First Quarter 2018 Financial and Operating Results - Company files IND for lead neoantigen vaccine program, GEN-009 - - ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification - - Conference call today at 9 am ET -"
02/15/2018 8-K Quarterly results
Docs: "Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results - GEN-009 neoantigen vaccine advancing to IND filing - - Balance sheet strengthened with $55m gross proceeds from January equity financing - - Conference call today at 9 am ET -"
11/02/2017 8-K Quarterly results
Docs: "Genocea Reports Third Quarter 2017 Financial Results - SITC presentation to highlight ATLAS™ ability in neoantigen selection - - IND filing for neoantigen cancer vaccine, GEN-009, expected in Q1 2018 - - Conference call today at 9 am ET -"
08/09/2017 8-K Quarterly results
05/04/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
11/05/2015 8-K Investor presentation, Quarterly results
Docs: "Genocea Reports Third Quarter 2015 Financial Results - Company Reports Recent Milestones and Announces Expansion of ATLAS TM Technology into Immuno-Oncology - - Conference Call and Webcast Scheduled for 9:00 a.m. ET Today -",
"Management Presentation issued by Genocea Biosciences, Inc. on November 5, 2015"
08/06/2015 8-K Quarterly results
Docs: "Genocea Reports Second Quarter 2015 Financial Results"
05/07/2015 8-K Quarterly results
Docs: "Genocea Reports First Quarter 2015 Financial Results"
11/06/2014 8-K Quarterly results
Docs: "Genocea Reports Third Quarter 2014 Financial Results"
08/06/2014 8-K Quarterly results
Docs: "Genocea Reports Second Quarter 2014 Financial Results"
05/06/2014 8-K Quarterly results
Docs: "Genocea Reports First Quarter 2014 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy